Brought to you by 
Roche to develop and sell Transgene's HPV vaccines; terminated
16 Nov 2021
Executive Summary
Transgene SA (vaccines and immunotherapeutics for cancer and infections) has licensed Roche exclusive worldwide rights to develop and market its lead candidate TG4001 (MVA-HPV-IL2) for cervical intraepithelial neoplasia (CIN; precancerous cervical lesions) plus future vaccines for diseases transmitted by the human papilloma virus (HPV).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche to develop and sell Transgene's HPV vaccines; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice